| Literature DB >> 16332253 |
Otto Visser1, Joop H van Wijnen, Flora E van Leeuwen.
Abstract
BACKGROUND: Amsterdam Airport Schiphol is a major source of complaints about aircraft noise, safety risks and concerns about long term adverse health effects, including cancer. We investigated whether residents of the area around Schiphol are at higher risk of developing cancer than the general Dutch population.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16332253 PMCID: PMC1325225 DOI: 10.1186/1471-2458-5-127
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Summary of the results in μg/m3 (except benzo(a)pyrene: ng/m3) of the air quality monitoring system of the Schiphol area in 2002
| NO2 | year average | 40a | 38 | 38 | 31 |
| maximum | 200b | 163 | 544(1x > 200) | 124 | |
| CO | P98 (8 hours) | 9000 | 112 | 100 | 88 |
| P99,9 | 40000 | 134 | 165 | 160 | |
| O3 | maximum | 240c | 185 | 174 | 266 (2x > 240) |
| PM10 | average (year) | 40d,e | 26 | 24 | 28 |
| maximum (24 hours) | 50d,f | 81 (13x > 50) | 81 (8x > 50) | 132 (22x > 50) | |
| Benzene | year average | 10 | 1.4 | 1.1 | 0.7 |
| Black smoke | P98 (24 hours) | 90g | 42 | 48 | 34 |
| Benzo(a)pyrene | year average | 1 | 0.14 | ||
a as of 1-1-2010
b exceeding of the limit no more than 18 times per annum
c exceeding of the limit not more than 48 hours
d including factor 1.3
e as of 1-1-2005
f exceeding of the limit no more than 35 times per annum
g the limit expired in July 2001
PM10 = particulate matter <10 μm
Figure 1Noise exposure (in Kosten-units) in the Schiphol area in 1991. The area surrounded by the blue line indicates the core zone, the black line includes the total study area. The location of the three air quality monitoring stations are indicated by asterisks (*).
Some characteristics of the Schiphol study area
| Haarlemmermeer | 1161 | 8300 | 7820 | € 10 700 |
| 1175, 1435-8, 2143 | 6880 | 6015 | € 11 000 | |
| 2132 | 7815 | 10 965 | € 11 000 | |
| 2153 | 3520 | 3310 | € 10 500 | |
| Amstelveen | 1182 | 4075 | 3740 | € 11 500 |
| Haarlemmermeer | 1171 | 10 750 | 11 770 | € 13 200 |
| 2131 | 10 205 | 11 030 | € 11 400 | |
| 2151-2 | 11 925 | 22 260 | € 11 100 | |
| 2154-8, 2165 | 5585 | 5940 | € 10 300 | |
| Amstelveen | 1181, 1183 | 31 145 | 30 385 | € 12 400 |
| Amsterdam | 1067, 1081-3 | 34 960 | 35 080 | € 14 500 |
| Aalsmeer | 1431-3 | 21 740 | 22 870 | € 11 300 |
| Haarlemmerliede & Spaarnwoude | 1165, 2064-5 | 4900 | 5535 | € 10 800 |
* the national average in 1998 was € 10 000
† weighed average, rounded to € 100
Observed (O) and expected (E) number of cancers in subjects with residence in the Schiphol area according to site, gender and period of diagnosis, 1988–2003
| O | E | SIR | 95% CI | O | E | SIR | 95% CI | O | E | SIR | 95% CI | O | E | SIR | 95% CI | |
| All malignancies (C00–C96) | 13207 | 13007.9 | 1.00, 1.03 | 4624 | 4538.6 | 0.99, 1.05 | 4220 | 4125.1 | 0.99, 1.05 | 4363 | 4344.3 | 0.97, 1.03 | ||||
| adult males | 6697 | 6713.7 | 0.97, 1.02 | 2402 | 2363.5 | 0.98, 1.06 | 2145 | 2150.3 | 0.96, 1.04 | 2150 | 2199.9 | 0.94, 1.02 | ||||
| adult females | 6436 | 6235.3 | 1.01, 1.06 | 2190 | 2154.3 | 0.97, 1.06 | 2057 | 1956.5 | 1.01, 1.10 | 2189 | 2124.5 | 0.99, 1.07 | ||||
| children <15 | 74 | 58.9 | 0.99, 1.58 | 32 | 20.7 | 1.06, 2.18 | 18 | 18.3 | 0.58, 1.55 | 24 | 19.9 | 0.77, 1.79 | ||||
| Head & neck (C00–C14) | 282 | 272.9 | 0.92, 1.16 | 93 | 93.7 | 0.80, 1.22 | 91 | 85.9 | 0.85, 1.30 | 98 | 93.3 | 0.85, 1.28 | ||||
| males | 162 | 176.9 | 0.78, 1.07 | 53 | 62.8 | 0.63, 1.10 | 56 | 55.6 | 0.76, 1.31 | 53 | 58.4 | 0.68, 1.19 | ||||
| females | 120 | 96.0 | 1.04, 1.49 | 40 | 30.9 | 0.92, 1.76 | 35 | 30.3 | 0.80, 1.61 | 45 | 34.8 | 0.94, 1.73 | ||||
| Gastrointestinal tract (C15–C26) | 2889 | 2936.0 | 0.95, 1.02 | 1034 | 1049.3 | 0.93, 1.05 | 899 | 920.4 | 0.91, 1.04 | 956 | 966.3 | 0.93, 1.05 | ||||
| males | 1494 | 1538.0 | 0.92, 1.02 | 517 | 541.6 | 0.87, 1.04 | 470 | 482.3 | 0.89, 1.07 | 507 | 514.1 | 0.90, 1.08 | ||||
| females | 1395 | 1398.1 | 0.95, 1.05 | 517 | 507.7 | 0.93, 1.11 | 429 | 438.1 | 0.89, 1.08 | 449 | 452.3 | 0.90, 1.09 | ||||
| Respiratory system (C30–C34) | 1862 | 1975.1 | 0.90, 0.99 | 749 | 752.6 | 0.93, 1.07 | 542 | 627.1 | 0.79, 0.94 | 571 | 595.4 | 0.88, 1.04 | ||||
| males | 1378 | 1548.0 | 0.84, 0.94 | 604 | 626.3 | 0.89, 1.01 | 386 | 492.7 | 0.71, 0.87 | 388 | 429.0 | 0.82, 1.00 | ||||
| females | 484 | 427.1 | 1.03, 1.24 | 145 | 126.3 | 0.97, 1.35 | 156 | 134.5 | 0.98, 1.36 | 183 | 166.4 | 0.95, 1.27 | ||||
| Breast (C50) | 2087 | 1983.6 | 0.99, 1.11 | 679 | 676.4 | 0.93, 1.08 | 678 | 620.3 | 1.01, 1.18 | 730 | 686.9 | 0.99, 1.14 | ||||
| Female genital organs (C51–C58) | 710 | 730.7 | 0.90, 1.05 | 252 | 274.9 | 0.81, 1.04 | 237 | 232.9 | 0.89, 1.16 | 221 | 222.9 | 0.87, 1.13 | ||||
| Prostate (C61) | 1291 | 1230.9 | 0.99, 1.11 | 382 | 364.6 | 0.95, 1.16 | 470 | 421.2 | 1.02, 1.22 | 439 | 445.2 | 0.90, 1.08 | ||||
| Bladder & other urinary tract (C65–C68) | 543 | 517.2 | 0.96, 1.14 | 211 | 183.9 | 1.00, 1.31 | 172 | 163.7 | 0.90, 1.22 | 160 | 169.7 | 0.80, 1.10 | ||||
| males | 425 | 390.0 | 0.99, 1.20 | 173 | 139.7 | 1.06, 1.44 | 129 | 123.6 | 0.87, 1.24 | 123 | 126.7 | 0.81, 1.16 | ||||
| females | 118 | 127.3 | 0.77, 1.11 | 38 | 44.2 | 0.54, 1.29 | 43 | 40.1 | 0.78, 1.44 | 37 | 43.0 | 0.61, 1.19 | ||||
| Hematological malignancies (C81–C96) | 1044 | 935.2 | 1.05, 1.19 | 367 | 328.3 | 1.01, 1.24 | 334 | 291.2 | 1.03, 1.28 | 343 | 315.8 | 0.97, 1.21 | ||||
| males | 598 | 507.6 | 1.09, 1.28 | 210 | 177.3 | 1.03, 1.36 | 184 | 157.8 | 1.00, 1.35 | 204 | 172.6 | 1.03, 1.36 | ||||
| females | 446 | 427.6 | 0.95, 1.14 | 157 | 151.0 | 0.88, 1.22 | 150 | 133.4 | 0.95, 1.32 | 139 | 143.2 | 0.82, 1.15 | ||||
| Hodgkin lymphoma | 48 | 61.2 | 0.58, 1.04 | 19 | 23.6 | 0.48, 1.26 | 12 | 17.7 | 0.35, 1.18 | 17 | 19.9 | 0.50, 1.37 | ||||
| non-Hodgkin lymphoma | 516 | 423.5 | 1.12, 1.33 | 176 | 150.0 | 1.01, 1.36 | 181 | 133.5 | 1.17, 1.57 | 159 | 140.0 | 0.97, 1.33 | ||||
| plasma cell tumors | 169 | 156.1 | 0.93, 1.26 | 59 | 55.6 | 0.81, 1.37 | 56 | 51.3 | 0.82, 1.42 | 54 | 49.3 | 0.82, 1.43 | ||||
| acute lymphoblastic leukemia | 39 | 29.1 | 0.95, 1.83 | 17 | 10.2 | 0.97, 2.67 | 8 | 8.8 | 0.39, 1.79 | 14 | 10.2 | 0.75, 2.30 | ||||
| chronic lymphocytic leukemia | 92 | 101.2 | 0.73, 1.11 | 33 | 35.0 | 0.65, 1.32 | 29 | 35.2 | 0.55, 1.18 | 30 | 31.0 | 0.65, 1.38 | ||||
| acute myeloid leukemia | 109 | 97.8 | 0.92, 1.34 | 40 | 33.9 | 0.84, 1.61 | 33 | 31.4 | 0.72, 1.48 | 36 | 32.4 | 0.78, 1.54 | ||||
| other | 71 | 66.2 | 0.84, 1.35 | 23 | 20.1 | 0.73, 1.72 | 15 | 13.3 | 0.63, 1.86 | 33 | 32.8 | 0.69, 1.41 | ||||
| Other sites | 2499 | 2426.3 | 0.99, 1.07 | 857 | 815.0 | 0.98, 1.12 | 797 | 762.4 | 0.97, 1.12 | 845 | 848.9 | 0.93, 1.06 | ||||
| males | 1391 | 1355.5 | 0.97, 1.08 | 485 | 462.8 | 0.96, 1.15 | 462 | 427.2 | 0.99, 1.18 | 444 | 465.5 | 0.87, 1.05 | ||||
| females | 1108 | 1070.8 | 0.97, 1.10 | 372 | 352.2 | 0.95, 1.17 | 335 | 335.2 | 0.90, 1.11 | 401 | 383.4 | 0.95, 1.15 | ||||
* p < 0.05; † p < 0.01; CI = confidence interval; E = expected number; O = observed number; SIR = standardized incidence ratio
Number of cancer cases in subjects with residence in the Schiphol area according to site, gender and area of residence, 1988–2003
| All malignancies (C00–C95) | 10 855 | 1.01 | 0.99, 1.03 | 2 352 | 1.06* | 1.02, 1.10 | 1.05* | 1.01, 1.10 |
| adult males | 5 440 | 0.98 | 0.96, 1.01 | 1 257 | 1.07 | 1.01, 1.13 | 1.09* | 1.03, 1.16 |
| adult females | 5 356 | 1.03 | 1.00, 1.06 | 1 080 | 1.04 | 0.98, 1.11 | 1.01 | 0.95, 1.08 |
| children (<15) | 59 | 1.25 | 0.95, 1.61 | 15 | 1.29 | 0.72, 2.13 | 1.04 | 0.59, 1.83 |
| Head & neck (C00–C14) | 238 | 1.06 | 0.93, 1.21 | 44 | 0.90 | 0.65, 1.21 | 0.85 | 0.61, 1.17 |
| males | 133 | 0.92 | 0.77, 1.09 | 29 | 0.89 | 0.59, 1.27 | 0.96 | 0.64, 1.44 |
| females | 105 | 1.32* | 1.08, 1.59 | 15 | 0.93 | 0.52, 1.53 | 0.70 | 0.41, 1.21 |
| Gastrointestinal tract (C15–C26) | 2 422 | 0.99 | 0.95, 1.03 | 467 | 0.96 | 0.87, 1.05 | 0.97 | 0.88, 1.07 |
| males | 1 240 | 0.98 | 0.92, 1.03 | 254 | 0.95 | 0.83, 1.07 | 0.97 | 0.85, 1.11 |
| females | 1 182 | 1.00 | 0.95, 1.06 | 213 | 0.97 | 0.85, 1.11 | 0.97 | 0.84, 1.12 |
| Respiratory system (C30–C34) | 1 484 | 0.91* | 0.86, 0.96 | 378 | 1.10 | 0.99, 1.22 | 1.21* | 1.08, 1.35 |
| males | 1 085 | 0.85* | 0.80, 0.90 | 293 | 1.08 | 0.96, 1.21 | 1.27* | 1.12, 1.45 |
| females | 399 | 1.13* | 1.02, 1.24 | 85 | 1.17 | 0.93, 1.44 | 1.04 | 0.82, 1.31 |
| Breast (C50) | 1 731 | 1.05* | 1.01, 1.11 | 356 | 1.04 | 0.93, 1.15 | 0.99 | 0.88, 1.11 |
| Female genital organs (C51–C58) | 567 | 0.93 | 0.86, 1.01 | 143 | 1.16 | 0.98, 1.37 | 1.24* | 1.04, 1.50 |
| Prostate (C61) | 1 044 | 1.02 | 0.96, 1.08 | 247 | 1.19* | 1.05, 1.35 | 1.17* | 1.02, 1.34 |
| Bladder & other urinary tract (C65–C68) | 468 | 1.09 | 0.99, 1.19 | 102 | 1.18 | 0.96, 1.43 | 1.16 | 0.93, 1.43 |
| males | 341 | 1.05 | 0.95, 1.17 | 84 | 1.26* | 1.01, 1.56 | 1.20 | 0.94, 1.52 |
| females | 100 | 0.93 | 0.76, 1.13 | 18 | 0.92 | 0.54, 1.44 | 0.98 | 0.60, 1.63 |
| Hematological malignancies (C81–C96) | 855 | 1.10* | 1.03, 1.18 | 189 | 1.17* | 1.01, 1.35 | 1.06 | 0.91, 1.24 |
| males | 483 | 1.16* | 1.06, 1.27 | 115 | 1.26* | 1.04, 1.51 | 1.09 | 0.89, 1.33 |
| females | 372 | 1.04 | 0.94, 1.15 | 74 | 1.06 | 0.83, 1.33 | 1.02 | 0.79, 1.31 |
| Other sites | 2 073 | 1.03 | 0.99, 1.08 | 426 | 1.02 | 0.93, 1.12 | 0.99 | 0.89, 1.10 |
| males | 1 148 | 1.03 | 0.97, 1.09 | 243 | 1.01 | 0.89, 1.14 | 0.98 | 0.85, 1.12 |
| females | 925 | 1.03 | 0.97, 1.10 | 183 | 1.04 | 0.90, 1.20 | 1.01 | 0.86, 1.18 |
* p < 0.05
# reference population: the Netherlands 1989–2003
## ratio of the SIR of the core zone and the SIR of the ring zone
CI = confidence interval; SIR = standardized incidence ratio; RR = rate ratio